Liposomal daunorubicin as treatment for Kaposi’s sarcoma
暂无分享,去创建一个
[1] Y. Chang,et al. Kaposi's sarcoma. , 2000, The New England journal of medicine.
[2] F. Puppo,et al. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. , 2002, AIDS.
[3] L. Pantanowitz,et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S M Gruner,et al. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. , 1998, Biochimica et biophysica acta.
[5] D. Hanahan,et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. , 1998, The Journal of clinical investigation.
[6] S. Krown,et al. Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: A Proposal for Uniform Evaluation, Response, and Staging Criteria , 1989 .
[7] H. Dvorak,et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.
[8] L. Chieco‐Bianchi,et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. , 2000, Journal of the National Cancer Institute. Monographs.
[9] N. Stavrianeas,et al. Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. , 2002, Journal of acquired immune deficiency syndromes.
[10] A. Tulpule,et al. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Handa,et al. Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation. , 1975, Gan.
[12] A. Di Marco,et al. Daunomycin: A New Antibiotic with Antitumor Activity , 1963, Cancer chemotherapy reports.
[13] P. Cullis,et al. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. , 1992, The Journal of biological chemistry.
[14] Rakesh K. Jain,et al. Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.
[15] L. Grochow,et al. A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics , 1998 .
[16] V Bĕhal,et al. Bioactive products from Streptomyces. , 2000, Advances in applied microbiology.
[17] J. Spano,et al. Phase IV Study of Liposomal Daunorubicin (DaunoXome) in AIDS-Related Kaposi Sarcoma , 2002, American journal of clinical oncology.
[18] M. Zucchetti,et al. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma , 2000, Cancer Chemotherapy and Pharmacology.
[19] V. Calvez,et al. The influence of highly active antiretroviral therapy on AIDS‐associated Kaposi's sarcoma , 1999, The British journal of dermatology.
[20] F. Real,et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. , 1983, The New England journal of medicine.
[21] J. Doroshow,et al. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. , 1986, The Journal of biological chemistry.
[22] K. Gelmon,et al. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection , 1998, Cancer Chemotherapy and Pharmacology.
[23] L. Gesualdo,et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. , 2005, The New England journal of medicine.
[24] C. Pellet,et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV‐related Kaposi's sarcoma , 1998, AIDS.
[25] A. Kuten,et al. Radiation therapy for non-AIDS associated (classic and endemic African) and epidemic Kaposi's sarcoma. , 1994, International journal of radiation oncology, biology, physics.
[26] F. Real,et al. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Goedert,et al. Trends in cancer risk among people with AIDS in the United States 1980–2002 , 2006, AIDS.
[28] A. Bangham,et al. Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.
[29] Abrams Rm,et al. Liposome disposition in vivo: effects of pre-dosing with lipsomes. , 1980 .
[30] P. Cullis,et al. Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. , 1998, Advanced drug delivery reviews.
[31] D. Greenblatt,et al. Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir , 1998, Journal of clinical pharmacology.
[32] A. Jemal,et al. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. , 2002, Journal of the National Cancer Institute.
[33] D. Dittmer,et al. Long-Term-Infected Telomerase-Immortalized Endothelial Cells: a Model for Kaposi's Sarcoma-Associated Herpesvirus Latency In Vitro and In Vivo , 2006, Journal of Virology.
[34] E. Cesarman,et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. , 1995, The New England journal of medicine.
[35] F. Sigaux,et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. , 1995, Blood.
[36] G. Weissmann,et al. Phospholipid spherules (liposomes) as a model for biological membranes. , 1968, Journal of lipid research.
[37] D. Crothers,et al. Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. , 1982, Biochemistry.
[38] L. Liu,et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.
[39] J. Chaires. Biophysical chemistry of the daunomycin-DNA interaction. , 1990, Biophysical chemistry.
[40] N. Osheroff,et al. Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism (*) , 1995, The Journal of Biological Chemistry.
[41] P. Monini,et al. Antitumour effects of antiretroviral therapy , 2004, Nature Reviews Cancer.
[42] S. Krown,et al. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] A. Levine,et al. Recent Advances in Acquired Immunodeficiency Syndrome (AIDS)‐related Lymphoma , 2005, CA: a cancer journal for clinicians.
[44] N. Damjanov,et al. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. , 2001, Oncology.
[45] C. Boshoff,et al. Kaposi sarcoma herpesvirus : new perspectives , 2007 .
[46] Ling Wang,et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. , 2007, Blood.
[47] S. Crooke,et al. Structure-activity relationships of anthracyclines relative to effects on macromolecular syntheses. , 1978, Molecular pharmacology.
[48] D. Alberts,et al. The pharmacokinetics of daunomycin in man , 1971, Clinical pharmacology and therapeutics.
[49] K. Gelmon,et al. Phase I study of liposomal vincristine. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] P. Johnson,et al. Drug delivery systems : fundamentals and techniques , 1987 .
[51] C. Presant,et al. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma , 1993, The Lancet.
[52] C. Hunt,et al. Liposome disposition in vivo: effects of pre-dosing with lipsomes. , 1980, Research communications in chemical pathology and pharmacology.
[53] A. Tulpule,et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] C. Bennett,et al. Pharmacoeconomics of liposomal anthracycline therapy. , 2004, Seminars in oncology.
[55] J. Kigula-Mugambe,et al. Epidemic and endemic Kaposi's sarcoma: a comparison of outcomes and survival after radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[56] U. Persson,et al. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. , 1999, Acta oncologica.
[57] Kelvin,et al. Redox Cycling of Anthracyclines by Cardiac Mitochondria , 2022 .
[58] W. Wilson,et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. , 2003, Blood.
[59] P. Sedmera,et al. Anthracyclines , 1977, Folia Microbiologica.
[60] D. V. Von Hoff,et al. Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.
[61] D. Osoba,et al. Use of liposomal anthracyclines in Kaposi's sarcoma. , 2004, Seminars in oncology.
[62] Theresa M Allen,et al. Advantages of liposomal delivery systems for anthracyclines. , 2004, Seminars in oncology.
[63] C. Casper. Defining a role for antiviral drugs in the treatment of persons with HHV-8 infection. , 2006, Herpes : the journal of the IHMF.
[64] M. Manfait,et al. Selective analysis of antitumor drug interaction with living cancer cells as probed by surface-enhanced Raman spectroscopy , 2004, European Biophysics Journal.
[65] F. Lacombe,et al. Intercalation of anthracyclines into living cell DNA analyzed by flow cytometry. , 1992, Cytometry.
[66] G. Betageri,et al. Liposome Drug Delivery Systems , 1993 .
[67] P. Elliott. Pathogenesis of cardiotoxicity induced by anthracyclines. , 2006, Seminars in oncology.
[68] M. Bally,et al. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. , 1986, Biochimica et biophysica acta.
[69] J. V. Von Roenn,et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[70] D. Coulter,et al. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. , 1992, Cancer research.
[71] J. Metcalf,et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. , 1988, Lancet.
[72] Ulrich Beyer,et al. Liposomal encapsulated anti-cancer drugs. , 2005, Anti-cancer drugs.
[73] S. Stewart,et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] J. Pitha,et al. A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.
[75] T. Quinn,et al. HIV/AIDS in Women: An Expanding Epidemic , 2005, Science.
[76] T. Allen. Toxicity of drug carriers to the mononuclear phagocyte system , 1988 .
[77] L. Grochow,et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] M. Bower,et al. Cardiotoxicity after liposomal anthracyclines. , 2004, The Lancet. Oncology.
[79] D. Friend,et al. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. , 1992, Cancer research.
[80] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[81] B. Sinha. Free radicals in anticancer drug pharmacology. , 1989, Chemico-biological interactions.
[82] M. Baseler,et al. ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA , 1988, The Lancet.
[83] J. Tappero,et al. Kaposi's sarcoma: Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy , 1993 .
[84] J. V. Von Roenn,et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] A. Tulpule,et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] L. Liu,et al. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.
[87] J. V. Von Roenn,et al. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.